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DECREASE OF URINARY CORTICOSTEROIDS FOLLOWING APPLICATION
OF FLUOCINOLONE ACETONIDE UNDER AN OCCLUSIVE DRESSING*
ROBERT B. SCOGGINS, M.D.
Since the advent of topical corticosteroid
therapy, numerous studies of possible systemic
effects have appeared in the literature. Most
have demonstrated no absorption with the mate-
rials and methods used (1—6). In one study ab-
sorption of hydrocortisone-4-C'4 but in small
amount and in a possibly inert form was shown
(7). Convincing evidence of fludrocortisone
acetate absorption was reported in 1955 (8).
One report presented radioautographic evidence
of hydro cortisone-C14 absorption (9). Another
showed a decrease in circulating eosinophils
following meticortelone application (10). The
present widespread use of topical corticoste-
roids with occlusive plastic film dressings (11)
prompted an investigation of the possibility of
percutaneous absorption when applied over large
body areas.
Methods
Two patients with severe generalized psoriasis
were treated with fluocinolone acetonide (6z,
9a difluoro-16a hydroxyprednisolone 16, 17
acetonide) 0.025% cream which was applied
every 12 hours in an amount sufficient to cover
the entire body, followed by Saran Wrap (Dow
Chemical Co.) dressing of the whole body exclud-
ing head and genitalia.
Patient 1 was a 48-year-old obese white female
without other significant disease; 60 g. of cream
(15 mg. fluocinolone) was applied twice daily.
Patient 2 was a 44-year-old white male chronic
alcoholic with evidence of early Laennec's cirrho-
sis; 45 g. of cream (11.25 mg fluocino]one) was
applied twice daily. Neither had recently re-
ceived corticosteroids in any form. Levels of 17-
hydroxycorticosteroids were measured by a
modified Porter-Silver method (12) and 17-
ketosteroids were determined by the Vester-
guard method (13) in 24-hour urine specimens.
Results
As shown in the table, marked depression of
urinary steroid excretion to below the normal
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range occurred on this regimen, indicating suffi-
cient absorption of fluocinolone to cause suppres-
sion of endogenous adrenocorticosteroid produc-
tion. Clinical response was excellent. Return of
urinary steroids to normal levels occurred upon
cessation of topical applications. The procedure
was repeated in the patients at a time when each
was experiencing a moderate recrudescence of
skin lesions similar to that frequently seen in
psoriatics upon discontinuance of systemic cor-
ticosteroid therapy. Again, 17-hydroxycorti-
costeroid and 17-ketosteroid excretion fell
abruptly and significantly. In patient 2, the
occlusive wrapping was then discontinued, this
at a time when his skin disease was notably
improved. Urinary steroid excretion promptly
increased despite continued application of fluo-
cinolone without occlusive dressing. During this
final treatment period the skin lesions remained
improved.
Discussion
The above data provide sufficient basis to
suggest that the same precautions be observed
in the use of potent corticosteroid preparations
under plastic film dressings over large areas of
diseased skin that are observed in the adminis-
tration of corticosteroids by any other route.
The complications of systemic corticosteroid
administration, both those immediately related
to greater-than-physiologic dosage and those of
potential adrenal insufficiency following with-
drawal of exogenously administered preparations,
need not be reiterated here.
Further studies are in progress in an effort
to clarify the dose-response relationship, to
confirm and extend the data by these and other
parameters in patients and subjects with normal
skin, and to determine the percutaneous absorp-
tion of certain other preparations. Abandonment
of this useful therapy is not suggested at the
present time, but caution is indicated in its
use until its pharmacology is better understood.
Summary
Significant percutaneous absorption of physio-
logically active drug is shown with fluocinolone
acetonide application over large body areas with
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TABLE
Alterations in urinary steroids (mg/24 hrs.) in
psoriatic patients during fluocinolone therapy
Patient I Patient 2
Day
__llHOH
Control 0 4.5 5.5 0 4.1
1 ++ 1.5 0.9 ++ 3.7
2 ++ 3.5 0.4 ++ 1.5
3 ++ 1.8 0.2 ++ 1.2
4 ++ L2 0.5 ++ —
5 ++ 0.5 0.5 ++ 0.3
6 ++ 0.7 0.5 ++ 1.2
7 ++ 0.7 0.7 ++ 1.3
8 0 0.6 0.4 ++ 0.7
9 0 2.5 0.8 ++ 0.4
10 0 2.8 0.7 ++ 0.7
11 0 — — 0 —
12 0 — 0.4 0 2.7
13 0 5.0 4.5 0 4.9
14 0 — — 0 6.8
15 0 3.0 1.8 0 6.3
16 0 — — 0 7.0
17 0 — — 0 3.1
18 0 — — 0 4.0
19 0 4.0 1.5 ++ 3.8
20 0 3.2 1.0 ++ 2.1
21 ++ 2.7 0.2 ++ 1.7
22 ++ 1.3 0.0 ++ 1.4
23 ++ 2.7 0.0 ++ 1.6
24 ++ 1.4 0.0 ++ 1.4
25 ++ 1.2
End of Study
26 + 1.0
27 + 1.5
28 + 2.4
29 + 5.4
30 + 4.5
31 + 6.2
32 + 4.9
33 + 5.5
17—
Keto
5.1
1.4
1.9
1.7
1.7
1.1
1.9
1.5
1.7
1.1
2.0
1.7
4.2
5.2
6.2
3.1
8.1
2.0
5.4
6.0
2.9
2.0
2.6
2.1
3.8
1.7
5.0
11.0
7.3
8.0
16.5
12.8
9.0
that the same precaution should be exercised
in the use of this therapeutic modality* that would
be used in the administration of cortieosteroids
by oral or parenteral routes.
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* Two patients with atopic dermatitis treated
in the same way with triamcinolone acetonide
0.1% cream and flurandrenolone 0.05% cream in
45 gm. amounts b.i.d. showed similar depression
of urinary steroid levels.
++ Fluoeinolone with wrap
+ Fluocinolone without wrap
1 No therapy
an occlusive dressing in two patients with ex-
tensive psoriasis, with repeated confirmation in
each patient. These preliminary data suggest
